Ann: Appendix 4C - Quarterly, page-6

This gave me a chuckle this morning so thank you for that,

Have a look at the board and their past history.
The staff will be made up of medical professionals and doctors.

Emyria are operating 7 clinical sites around Australia with over 5000 patients, this is where they are getting their RWE that provides the data that supports the drug registration part of the business.

This is an extremely cost effecting way of getting a drug to market which EMD has been saying in their presentations for a while now.

What exactly would you like them to spend money on right now?

They know the compounds they are working on very well, you know because they are overly qualified doctors.

Money will be spent on these essential things going forward
"Eurofins will perform a series of targeted CNS screens to support the identification and development of lead compounds"

"The Palantir Foundry Builders program was established to allow select companies access to powerful and highly secure data integration and analysis software typically only available to major enterprises"

So how much less should they pay their doctors?
and where should they be throwing money at instead?